Ocular Therapeutix (OCUL) Cash from Financing Activities (2013 - 2026)
Ocular Therapeutix's quarterly Cash from Financing Activities came in at $294000.0 in Q1 2026, down 92.97% year-on-year from $4.2 million in Q1 2025, and down 99.93% quarter-over-quarter from $449.4 million in Q4 2025.
Ocular Therapeutix has reported Cash from Financing Activities for 14 years, with the latest figure at $294000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 92.97% year-over-year to $294000.0; the trailing twelve-month figure through Mar 2026 stood at $557.8 million (up 3601.61% YoY), and the FY2025 full-year result was $561.7 million, up 69.14% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $294000.0, down from $449.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $449.4 million in Q4 2025, with the low at $78000.0 in Q1 2023.
- Average Cash from Financing Activities over 5 years is $62.7 million, with a median of $4.2 million recorded in 2025.
- Year-over-year, Cash from Financing Activities surged 411724.36% in 2024 and sank 98.7% in 2025.
- Tracing OCUL's Cash from Financing Activities over 5 years: stood at $458000.0 in 2022, then surged by 23517.9% to $108.2 million in 2023, then plunged by 95.83% to $4.5 million in 2024, then jumped by 9857.37% to $449.4 million in 2025, then sank by 99.93% to $294000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $294000.0 (Q1 2026), $449.4 million (Q4 2025), and $10.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 294,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 294,000.00 |
| Mar 31, 2026 | 294,000.00 |
| Dec 31, 2025 | 449.38 Mn |
| Dec 31, 2025 | 449.38 Mn |
| Sep 30, 2025 | 10.36 Mn |
| Sep 30, 2025 | 10.36 Mn |
| Jun 30, 2025 | 97.81 Mn |
| Jun 30, 2025 | 97.81 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Sep 30, 2024 | 4.18 Mn |
| Sep 30, 2024 | 4.18 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Mar 31, 2024 | 321.22 Mn |
| Mar 31, 2024 | 321.22 Mn |
| Dec 31, 2023 | 108.17 Mn |
| Dec 31, 2023 | 108.17 Mn |
| Sep 30, 2023 | 51.94 Mn |
| Sep 30, 2023 | 51.94 Mn |
| Jun 30, 2023 | 9.65 Mn |
| Jun 30, 2023 | 9.65 Mn |
| Mar 31, 2023 | 78,000.00 |
| Mar 31, 2023 | 78,000.00 |
| Dec 31, 2022 | 458,000.00 |
| Dec 31, 2022 | 458,000.00 |
| Sep 30, 2022 | 374,000.00 |
| Sep 30, 2022 | 374,000.00 |
| Jun 30, 2022 | 493,000.00 |
| Jun 30, 2022 | 493,000.00 |
| Mar 31, 2022 | 129,000.00 |
| Mar 31, 2022 | 129,000.00 |
| Dec 31, 2021 | 667,000.00 |
| Dec 31, 2021 | 667,000.00 |
| Sep 30, 2021 | 679,000.00 |
| Sep 30, 2021 | 679,000.00 |
| Jun 30, 2021 | 2.67 Mn |
| Jun 30, 2021 | 2.67 Mn |
| Mar 31, 2021 | -1.16 Mn |
| Mar 31, 2021 | -1.16 Mn |
| Dec 31, 2020 | 163.91 Mn |
| Dec 31, 2020 | 163.91 Mn |
| Sep 30, 2020 | 220,000.00 |
| Sep 30, 2020 | 220,000.00 |
| Jun 30, 2020 | 51.06 Mn |
| Jun 30, 2020 | 51.06 Mn |
| Mar 31, 2020 | 12.82 Mn |
| Mar 31, 2020 | 12.82 Mn |
| Dec 31, 2019 | 9.09 Mn |
| Dec 31, 2019 | 9.09 Mn |
| Sep 30, 2019 | 18.61 Mn |
| Sep 30, 2019 | 18.61 Mn |
| Jun 30, 2019 | 5.34 Mn |
| Jun 30, 2019 | 5.34 Mn |
| Mar 31, 2019 | 42.30 Mn |
| Mar 31, 2019 | 42.30 Mn |
| Dec 31, 2018 | 16.33 Mn |
| Dec 31, 2018 | 16.33 Mn |
| Sep 30, 2018 | 11.37 Mn |
| Sep 30, 2018 | 11.37 Mn |
| Jun 30, 2018 | 6.71 Mn |
| Jun 30, 2018 | 6.71 Mn |
| Mar 31, 2018 | 34.23 Mn |
| Mar 31, 2018 | 34.23 Mn |
| Dec 31, 2017 | 1.21 Mn |
| Dec 31, 2017 | 1.21 Mn |
| Sep 30, 2017 | 1.53 Mn |
| Sep 30, 2017 | 1.53 Mn |
| Jun 30, 2017 | 796,000.00 |
| Jun 30, 2017 | 796,000.00 |
| Mar 31, 2017 | 28.48 Mn |
| Mar 31, 2017 | 28.48 Mn |
| Dec 31, 2016 | 693,000.00 |
| Dec 31, 2016 | 693,000.00 |
| Sep 30, 2016 | 78,000.00 |
| Sep 30, 2016 | 78,000.00 |
| Jun 30, 2016 | 3,000.00 |
| Jun 30, 2016 | 3,000.00 |
| Mar 31, 2016 | -189,000.00 |
| Mar 31, 2016 | -189,000.00 |
| Dec 31, 2015 | 308,000.00 |
| Dec 31, 2015 | 308,000.00 |
| Sep 30, 2015 | -201,000.00 |
| Sep 30, 2015 | -201,000.00 |
| Jun 30, 2015 | 65.73 Mn |
| Jun 30, 2015 | 65.73 Mn |
| Mar 31, 2015 | -137,000.00 |
| Mar 31, 2015 | -137,000.00 |
| Dec 31, 2014 | -106,000.00 |
| Dec 31, 2014 | -106,000.00 |
| Sep 30, 2014 | 67.56 Mn |
| Sep 30, 2014 | 67.56 Mn |
| Jun 30, 2014 | 11.95 Mn |
| Jun 30, 2014 | 11.95 Mn |
| Mar 31, 2014 | -433,000.00 |
| Mar 31, 2014 | -433,000.00 |
| Dec 31, 2013 | -449,000.00 |
| Dec 31, 2013 | -449,000.00 |
| Sep 30, 2013 | -454,000.00 |
| Sep 30, 2013 | -454,000.00 |